Stock Analysis

Aravive Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Source: Shutterstock

Aravive (NASDAQ:ARAV) Full Year 2022 Results

Key Financial Results

  • Revenue: US$9.14m (up 23% from FY 2021).
  • Net loss: US$76.3m (loss widened by 95% from FY 2021).
  • US$2.10 loss per share (further deteriorated from US$1.95 loss in FY 2021).

ARAV Products In Clinical Trials

  • Phase I: 1.
  • Phase II: 3.
  • Phase III: 1.
NasdaqGS:ARAV Earnings and Revenue Growth March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aravive Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 9.8%. Earnings per share (EPS) missed analyst estimates by 16%.

Looking ahead, revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 14% from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with Aravive (including 2 which are a bit concerning).

What are the risks and opportunities for Aravive?

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States.

View Full Analysis


  • Trading at 55.6% below our estimate of its fair value

  • Revenue is forecast to grow 59.88% per year


  • Has less than 1 year of cash runway

  • Shareholders have been substantially diluted in the past year

  • Volatile share price over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report